GlaxoSmithKline PLC ADR
$ 58.35
2.14%
17 Apr - close price
- Market Cap 117,546,541,000 USD
- Current Price $ 58.35
- High / Low $ 58.35 / 57.43
- Stock P/E 15.48
- Book Value 11.08
- EPS 3.77
- Next Earning Report 2026-04-29
- Dividend Per Share $0.66
- Dividend Yield 3.04 %
- Next Dividend Date -
- ROA 0.10 %
- ROE 0.43 %
- 52 Week High 61.21
- 52 Week Low 34.48
About
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Analyst Target Price
$57.65
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-10-29 | 2025-07-30 | 2025-04-30 | 2025-02-05 | 2024-10-30 | 2024-07-31 | 2024-05-01 | 2024-01-31 | 2023-11-01 | 2023-07-26 | 2023-04-26 |
| Reported EPS | 0.6969 | 1.4562 | 1.24 | 1.2 | 0.58 | 1.29 | 1.1 | 1.09 | 0.72 | 1.28 | 0.97 | 0.9 |
| Estimated EPS | 0.6378 | 1.17 | 1.11 | 1.04 | 0.49 | 1.16 | 0.99 | 0.91 | 0.76 | 1.14 | 0.87 | 0.82 |
| Surprise | 0.0591 | 0.2862 | 0.13 | 0.16 | 0.09 | 0.13 | 0.11 | 0.18 | -0.04 | 0.14 | 0.1 | 0.08 |
| Surprise Percentage | 9.2662% | 24.4615% | 11.7117% | 15.3846% | 18.3673% | 11.2069% | 11.1111% | 19.7802% | -5.2632% | 12.2807% | 11.4943% | 9.7561% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.19 |
| Currency | GBP |
Previous Dividend Records
| Apr 2026 | Jan 2026 | Jan 1970 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-04-09 | 2026-01-08 | None | 2025-07-10 | 2025-04-10 | 2025-01-09 | 2024-10-10 | 2024-07-11 | 2024-04-11 | 2024-01-11 |
| Amount | $0.485604 | $0.417088 | $0.428118 | $0.429088 | $0.400652 | $0.389052 | $0.385671 | $0.376185 | $0.4060608 | $0.3397772 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GSK
2026-04-20 06:30:05
GSK has continued its share buyback program, repurchasing 330,000 ordinary shares on April 17, 2026, for £7 million, adding them to treasury. This latest transaction brings total repurchases since February 2026 to nearly 19.9 million shares, reinforcing GSK’s capital-return strategy and updating shareholder voting-rights calculations. Spark, TipRanks' AI Analyst, rates GSK as Neutral due to strong profitability, constructive 2026 guidance, and reasonable valuation, despite technical overbought risk.
2026-04-20 06:21:05
GSK has received approval from China's National Medical Products Administration for Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma. This treatment, the only anti-BCMA approved in 2L+ multiple myeloma in China, demonstrated a 42% reduction in the risk of death and nearly tripled median progression-free survival in the DREAMM-7 phase III trial. Blenrep offers a new, fully outpatient anti-BCMA therapy, aiming to meet the growing need for effective and accessible treatments in China, where multiple myeloma incidence has doubled.
2026-04-20 01:39:05
4DMedical has secured a contract with GlaxoSmithKline (GSK) for lung imaging analytics services. This agreement was first reported by Reuters on April 19, 2026, at 09:34 pm EDT. Details of the contract are reserved for members of the MarketScreener platform.
2026-04-19 06:09:55
Google's 2026 Discover Core Update is transforming how investors access insights on GSK plc (ADR) stock, delivering tailored news on vaccines, pharma pipelines, and dividend strategies directly to mobile feeds without traditional searching. This mobile-first shift leverages user activity to proactively push relevant stories, offering a significant advantage for both U.S. and global investors tracking GSK's growth. The update rewards high-quality, visual content, enabling faster access to key developments, strategic pivots, R&D investments, and dividend information, thus leveling the playing field for retail investors.
2026-04-17 19:39:21
GSK plc is strategically focused on vaccines and specialty medicines, positioning it for steady growth and offering U.S. investors defensive healthcare exposure with global reach and dividend appeal. The company's emphasis on high-margin vaccines like Shingrix and Arexvy, along with its HIV treatments, aims to leverage demographic trends and innovation. Analysts maintain a positive outlook, citing strong vaccine momentum and HIV stability, suggesting GSK as a core holding for healthcare allocations.
2026-04-17 10:38:54
GSK plc announced it purchased 330,000 ordinary shares on April 16, 2026, as part of its ongoing share buyback program. These shares, bought at an average price of 2,125.06p, will be held as treasury shares, increasing the total held in treasury to 259,417,615. Following this transaction, the total number of ordinary shares in issue, excluding treasury shares, stands at 4,056,773,154, which also represents the company's total voting rights.
